drugset / Trial / NCT05828745
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CB06-036 in Subjects With Chronic Hepatitis B
RandomizedSequentialQuadruple-blindTreatment
Summary
CB06-036 is an investigational drug developed by Shanghai Zhimeng Biopharma Inc. for the treatment of Chronic Hepatitis B.
Timeline
- Start
- 2024-04-22
- Primary completion
- 2025-02-18
- Completion
- 2025-02-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CB06-036 | Unknown | 1.5 mg | — |
| Subject | CB06-036 | Unknown | 3 mg | — |